Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Emplicure has formed Nomination Comittee

Emplicure

EMPLICURE HAS FORMED NOMINATION COMITTEE

Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2023 is formed. The Nomination Committee  consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to give preference for more shareholders.

The Nomination Committee for the 2023 AGM is:

  • Thomas Lundqvist
  • Henrik Didner, for Monesi Förvaltnings AB
  • Peyman Pournouri
  • Gisela Sitbon (Chairman of the Board of Directors, Emplicure AB)

The Nomination Committee represents 47.7% of the votes in Emplicure.

The shores of the Nomination Committee:

The Nomination Committee shall, in short, prepare suggestions for the following to the AGM:

  • Election of Board of Directors (BoD)
  • Election of av Chairman of the Board
  • Resolution regarding number of auditors and auditor election
  • Remunerations for the BoD and the auditors
  • Principles that shall apply to the composition and work of the nomination committee for the next AGM

Primary contact for the Nomination Committee

Proposals by shareholders to the Nomination Committee may be submitted to the Chairman of the Board of Emplicure AB, Gisela Sitbon (gisela@sitbon.nu).

Certified Adviser

Certified Adviser is Erik Penser Bank AB.

The following documents can be retrieved from beQuoted
PM-Emplicure-Nomination-Committee 2023.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.